Skip to main content
News and Products

OCT company concludes successful financing round

By 10th February 2014No Comments

Michelson Diagnostics, the UK based
medical device company focused on the development of multi-beam Optical
Coherence Tomography (OCT) technology, has announced the first closing of its
Series A2 Financing round, which raised $ 3.25 million from existing investors.

The funds will be used for several purposes
including expanding OCT-based VivoSight sales in Germany, where the system was
launched in mid-2011 and where it is reimbursed for use in the diagnosis of
non-melanoma skin cancer (NMSC), the commonest skin malignancy. VivoSight is a
medical imaging system, using multi-beam OCT technology which can
non-invasively view all the layers of the skin in great detail.

The Company will also invest further in
the development of a compact, more portable second generation VivoSight System
with an anticipated lower cost of manufacture and enhanced functionality. Part
of the monies raised will be used to initiate US market access with a planned
pilot clinical study. The Company believes that the US is the largest single
market for the VivoSight system.

Michelson Diagnostics

Orpington, Kent, UK